{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:24:39Z","timestamp":1787793879138,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10067-020-04952-5","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T12:04:16Z","timestamp":1579781056000},"page":"1693-1698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0304-7993","authenticated-orcid":false,"given":"Francisco","family":"V\u00edlchez-Oya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Mar\u00eda","family":"S\u00e1nchez-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-8565","authenticated-orcid":false,"given":"Anna","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-0531","authenticated-orcid":false,"given":"Ana","family":"Pros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"4952_CR1","first-page":"569","volume":"11","author":"LE Shulman","year":"1984","unstructured":"Shulman LE (1984) Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 11:569\u2013570","journal-title":"J Rheumatol"},{"key":"4952_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/reum.2019.84813","volume":"57","author":"J Urzal","year":"2019","unstructured":"Urzal J, Cimbron M, Mendo\u00e7a T, Farinha F (2019) Eosinophilic fasciitis (Shulman\u2019s disease): review and comparative evaluation of seven patients. Reumatologia 57:85\u201390","journal-title":"Reumatologia"},{"key":"4952_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-017-0700-6","volume":"19","author":"DR Mazori","year":"2017","unstructured":"Mazori DR, Femia AN, Vleugels RA (2017) Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 19:74","journal-title":"Curr Rheumatol Rep"},{"key":"4952_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.alit.2019.03.001","volume":"68","author":"H Ihn","year":"2019","unstructured":"Ihn H (2019) Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int 68:437\u2013439","journal-title":"Allergol Int"},{"key":"4952_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jaci.2005.06.031","volume":"116","author":"I Gomes","year":"2005","unstructured":"Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ (2005) Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 116:796\u2013804","journal-title":"J Allergy Clin Immunol"},{"key":"4952_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.diii.2014.06.018","volume":"96","author":"T Kirchgesner","year":"2015","unstructured":"Kirchgesner T, Dallaudiere B, Omoumi P et al (2015) Eosinophilic fasciitis: typical abnormalities, variants and differential diagnosis of fasciae abnormalities using MR imaging. Diagn Interv Imaging 96:341\u2013348","journal-title":"Diagn Interv Imaging"},{"key":"4952_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/1346-8138.14160","volume":"45","author":"M Jinnin","year":"2018","unstructured":"Jinnin M, Yamamoto T, Asano Y et al (2018) Diagnostic criteria, severity classifications, and clinical guidelines of eosinophilic fasciitis. J Dermatol 45:88","journal-title":"J Dermatol"},{"key":"4952_CR8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10067-006-0525-6","volume":"26","author":"Y Endo","year":"2007","unstructured":"Endo Y, Tamura A, Matsushima Y, Iwasaki T, Hasegawa M, Nagai Y, Ishikawa O (2007) Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 26:1445\u20131451","journal-title":"Clin Rheumatol"},{"key":"4952_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","volume":"51","author":"D Lebeaux","year":"2012","unstructured":"Lebeaux D, Franc\u00e8s C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfoss\u00e9 M, Bourgeois P, Amoura Z, Cacoub P, Piette JC, S\u00e8ne D (2012) Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from series of 34 patients. Rheumatology (Oxford) 51:557\u2013561","journal-title":"Rheumatology (Oxford)"},{"key":"4952_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-4632.2007.03544.x","volume":"47","author":"L Bischoff","year":"2008","unstructured":"Bischoff L, Derk CT (2008) Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 47:29\u201335","journal-title":"Int J Dermatol"},{"key":"4952_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/03009742.2015.1067713","volume":"45","author":"FA Mendoza","year":"2016","unstructured":"Mendoza FA, Bai R, Kebede AG, Jimenez SA (2016) Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone. Scand J Rheumatol 45:129\u2013134","journal-title":"Scand J Rheumatol"},{"key":"4952_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-011-1866-3","volume":"31","author":"CU Manzini","year":"2012","unstructured":"Manzini CU, Sebastiani M, Giuggioli D, Manfredi A, Colaci M, Cesinaro AM, Ferri C (2012) D-penicillamine in the treatment of eosinophilic fasciitis: case reports and review of the literature. Clin Rheumatol 31:183\u2013187","journal-title":"Clin Rheumatol"},{"key":"4952_CR13","doi-asserted-by":"publisher","first-page":"212529","DOI":"10.7573\/dic.212529","volume":"7","author":"R Tull","year":"2018","unstructured":"Tull R, Hoover WD 3rd, De Luca JF et al (2018) Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context 7:212529","journal-title":"Drugs Context"},{"key":"4952_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/RHU.0b013e3181d56f73","volume":"16","author":"K Loupasakis","year":"2010","unstructured":"Loupasakis K, Derk CT (2010) Eosinophilic fasciitis in a pediatric patient. J Clin Rheumatol 16:129\u2013131","journal-title":"J Clin Rheumatol"},{"key":"4952_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1365-4632.2012.05741.x","volume":"53","author":"L Alonso-Castro","year":"2014","unstructured":"Alonso-Castro L, de las Heras E, Moreno C et al (2014) Eosinophilic fasciitis\/generalized morphea overlap successfully treated with azathioprine. Int J Dermatol 53:1386\u20131388","journal-title":"Int J Dermatol"},{"key":"4952_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/rheumatology\/21.4.218","volume":"21","author":"D Caspi","year":"1982","unstructured":"Caspi D, Fishel R, Varon M, Yona E, Baratz M, Yaron M (1982) Multisystem presentation of eosinophilic fasciitis. Rheumatol Rehabil 21:218\u2013221","journal-title":"Rheumatol Rehabil"},{"key":"4952_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jbspin.2009.06.001","volume":"76","author":"S Pimenta","year":"2009","unstructured":"Pimenta S, Bernardes M, Bernardo A, Brito I, Castro L, Sim\u00f5es-Ventura F (2009) Intravenous immunoglobulins to treat eosinophilic fasciitis: a case report. Joint Bone Spine 76:572\u2013574","journal-title":"Joint Bone Spine"},{"key":"4952_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP (2017) Standardization of the modified Rodnan skin score for the use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2:11\u201318","journal-title":"J Scleroderma Relat Disord"},{"key":"4952_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"key":"4952_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000246339","volume":"192","author":"Y Hashimoto","year":"1996","unstructured":"Hashimoto Y, Takahashi H, Matsuo S et al (1996) Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 192:136","journal-title":"Dermatology"},{"key":"4952_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000063916","volume":"205","author":"S Mosconi","year":"2002","unstructured":"Mosconi S, Streit M, Br\u00f6nimann M, Braathen L (2002) Eosinophilic fasciitis (Shulman syndrome). Dermatology 205:204","journal-title":"Dermatology"},{"key":"4952_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00000372-199610000-00004","volume":"18","author":"SR Granter","year":"1996","unstructured":"Granter SR, Barnhill RL, Duray PH (1996) Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 18:465","journal-title":"Am J Dermatopathol"},{"key":"4952_CR23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/rheumatology\/keq062","volume":"49","author":"D Khanna","year":"2010","unstructured":"Khanna D, Agrawal H, Clements PJ (2010) Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford) 49:1184\u20131188","journal-title":"Rheumatology (Oxford)"},{"key":"4952_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jbspin.2015.02.008","volume":"82","author":"F Espinoza","year":"2015","unstructured":"Espinoza F, Jorgensen C, Pers YM (2015) Efficacy of tocilizumab in the treatment of eosinophilic fasciitis: report of one case. Joint Bone Spine 82:460\u2013461","journal-title":"Joint Bone Spine"},{"key":"4952_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/120347540300700503","volume":"7","author":"A Drosou","year":"2003","unstructured":"Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA (2003) Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 7:382\u2013386","journal-title":"J Cutan Med Surg"},{"key":"4952_CR26","first-page":"65","volume":"24","author":"M Scheinberg","year":"2006","unstructured":"Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, Kiss MH, Chahade WH (2006) Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 24:65\u201369","journal-title":"Clin Exp Rheumatol"},{"key":"4952_CR27","first-page":"75","volume":"28","author":"JF Viallard","year":"2001","unstructured":"Viallard JF, Taupin JL, Ranchin V, Leng B, Pellegrin JL, Moreau JF (2001) Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 28:75\u201380","journal-title":"J Rheumatol"},{"key":"4952_CR28","doi-asserted-by":"publisher","unstructured":"Tanaka T, Narazakin M, Kishimoto T (2014) IL 6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a016295","DOI":"10.1101\/cshperspect.a016295"},{"key":"4952_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.berh.2019.01.011","volume":"32","author":"G Zacay","year":"2018","unstructured":"Zacay G, Levy Y (2018) Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Clin Rheumatol 32:563\u2013571","journal-title":"Best Pract Clin Rheumatol"},{"key":"4952_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF, van Laar J, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, M\u00fcller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomized controlled trial (faSScinate). Ann Rheum Dis 77:212\u2013220","journal-title":"Ann Rheum Dis"},{"key":"4952_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MD.0b013e3182899e78","volume":"92","author":"A de Masson","year":"2013","unstructured":"de Masson A, Bouaziz JD, Peffault de Latour R, Benhamou Y, Molu\u00e7on-Chabrot C, Bay JO, Laquerri\u00e8re A, Picquenot JM, Michonneau D, Leguy-Seguin V, Rybojad M, Bonnotte B, Jardin F, L\u00e9vesque H, Bagot M, Soci\u00e9 G (2013) Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) 92:69\u201381","journal-title":"Medicine (Baltimore)"},{"key":"4952_CR32","doi-asserted-by":"publisher","unstructured":"Frumholtz L, Sebert M, de Masson A et al (2017) Efficacy of eculizumab against eosinophilic fasciitis associated with paroxysmal nocturnal haemoglobinuria. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.13819","DOI":"10.1111\/jdv.13819"},{"key":"4952_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA (2018) A treatment of generalized deep morphea and eosinophilic fasciitis with Janus kinase inhibitor tofacitinib. JAAD Case Rep 4:443\u2013445","journal-title":"JAAD Case Rep"},{"key":"4952_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63:609\u2013621","journal-title":"Arthritis Rheum"},{"key":"4952_CR35","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"4952_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317\u2013328","journal-title":"N Engl J Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04952-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T19:48:50Z","timestamp":1611258530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04952-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04952-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Informed consent has been obtained from the patient to access and collect data from the medical record to be used in scientific publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of informed consent"}}]}}